Change in psoas muscle volume as a predictor of outcomes in patients treated with chemotherapy and radical cystectomy for muscle-invasive bladder cancer

Homayoun Zargar, Nima Almassi, Evan Z. Kovac, Cesar Ercole, Erick Remer, Brian Rinid, Andrew Stephenso, Jorge A. Garcia, Petros Grivas

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objective: Sarcopenia, or the age-related loss of skeletal muscle mass and function, has been investigated as a potential marker of adverse outcomes among surgical patients. Our aim was to assess for changes in psoas muscle volume (PMV) following administration of neoadjuvant chemotherapy (NAC) in patients with bladder cancer and to examine whether changes in PMV following NAC are predictive of perioperative complications, pathologic response or survival. Methods: During the period of 2009-2013, patients undergoing NAC and radical cystectomy (RC) at our institution with pre and post NAC cross sectional images available were included. Bilateral total psoas muscle volume (PMV) was obtained from pre- and post- NAC images and the proportion of PMV change was calculated by dividing the change PMV by pre-NAC PMV. Analyses for the assessment of factors predicting PMV loss, partial/complete pathologic response (pPR/pCR), complications, readmission, cancer specific (CSS), recurrence-free (RFS) and overall survival (OS) were performed. Results: Total of 60 patients had complete radiological data available. Post-NAC PMV and BMI declines were statistically significant, 4.9% and 0.05%, respectively. NAC dose reduction/delay was a significant predictor of PMV loss (coefficient B 4.6; 95%CI 0.05-9.2; p = 0.047). The proportion ofPMVdecline duringNACwas not a predictor of pPR, pCR, complications, readmission, CSS, RFS, or OS. Conclusions: We observed an interval decline in PMV during the period of NAC administration and this decline was more than it could be appreciated with changes in BMI during the same period. PMV decline was associated with the need for dose reduction/dose delay during NAC. In our series, PMV changes occurring during NAC administration were not predictive of pathologic response to chemotherapy, postoperative complications or survival.

Original languageEnglish (US)
Pages (from-to)57-63
Number of pages7
JournalBladder Cancer
Volume3
Issue number1
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

Fingerprint

Psoas Muscles
Cystectomy
Urinary Bladder Neoplasms
Drug Therapy
Muscles
Survival
Sarcopenia
Statistical Factor Analysis

Keywords

  • Bladder cancer
  • Complications
  • Cystectomy
  • Neoadjuvant chemotherapy
  • Pathologic response
  • Psoas muscle volume
  • Sarcopenia
  • Urothelial cancer

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Change in psoas muscle volume as a predictor of outcomes in patients treated with chemotherapy and radical cystectomy for muscle-invasive bladder cancer. / Zargar, Homayoun; Almassi, Nima; Kovac, Evan Z.; Ercole, Cesar; Remer, Erick; Rinid, Brian; Stephenso, Andrew; Garcia, Jorge A.; Grivas, Petros.

In: Bladder Cancer, Vol. 3, No. 1, 01.01.2017, p. 57-63.

Research output: Contribution to journalArticle

Zargar, Homayoun ; Almassi, Nima ; Kovac, Evan Z. ; Ercole, Cesar ; Remer, Erick ; Rinid, Brian ; Stephenso, Andrew ; Garcia, Jorge A. ; Grivas, Petros. / Change in psoas muscle volume as a predictor of outcomes in patients treated with chemotherapy and radical cystectomy for muscle-invasive bladder cancer. In: Bladder Cancer. 2017 ; Vol. 3, No. 1. pp. 57-63.
@article{aba9e87f8f9f4ae19325245664eed372,
title = "Change in psoas muscle volume as a predictor of outcomes in patients treated with chemotherapy and radical cystectomy for muscle-invasive bladder cancer",
abstract = "Objective: Sarcopenia, or the age-related loss of skeletal muscle mass and function, has been investigated as a potential marker of adverse outcomes among surgical patients. Our aim was to assess for changes in psoas muscle volume (PMV) following administration of neoadjuvant chemotherapy (NAC) in patients with bladder cancer and to examine whether changes in PMV following NAC are predictive of perioperative complications, pathologic response or survival. Methods: During the period of 2009-2013, patients undergoing NAC and radical cystectomy (RC) at our institution with pre and post NAC cross sectional images available were included. Bilateral total psoas muscle volume (PMV) was obtained from pre- and post- NAC images and the proportion of PMV change was calculated by dividing the change PMV by pre-NAC PMV. Analyses for the assessment of factors predicting PMV loss, partial/complete pathologic response (pPR/pCR), complications, readmission, cancer specific (CSS), recurrence-free (RFS) and overall survival (OS) were performed. Results: Total of 60 patients had complete radiological data available. Post-NAC PMV and BMI declines were statistically significant, 4.9{\%} and 0.05{\%}, respectively. NAC dose reduction/delay was a significant predictor of PMV loss (coefficient B 4.6; 95{\%}CI 0.05-9.2; p = 0.047). The proportion ofPMVdecline duringNACwas not a predictor of pPR, pCR, complications, readmission, CSS, RFS, or OS. Conclusions: We observed an interval decline in PMV during the period of NAC administration and this decline was more than it could be appreciated with changes in BMI during the same period. PMV decline was associated with the need for dose reduction/dose delay during NAC. In our series, PMV changes occurring during NAC administration were not predictive of pathologic response to chemotherapy, postoperative complications or survival.",
keywords = "Bladder cancer, Complications, Cystectomy, Neoadjuvant chemotherapy, Pathologic response, Psoas muscle volume, Sarcopenia, Urothelial cancer",
author = "Homayoun Zargar and Nima Almassi and Kovac, {Evan Z.} and Cesar Ercole and Erick Remer and Brian Rinid and Andrew Stephenso and Garcia, {Jorge A.} and Petros Grivas",
year = "2017",
month = "1",
day = "1",
doi = "10.3233/BLC-160080",
language = "English (US)",
volume = "3",
pages = "57--63",
journal = "Bladder Cancer",
issn = "2352-3727",
publisher = "IOS Press",
number = "1",

}

TY - JOUR

T1 - Change in psoas muscle volume as a predictor of outcomes in patients treated with chemotherapy and radical cystectomy for muscle-invasive bladder cancer

AU - Zargar, Homayoun

AU - Almassi, Nima

AU - Kovac, Evan Z.

AU - Ercole, Cesar

AU - Remer, Erick

AU - Rinid, Brian

AU - Stephenso, Andrew

AU - Garcia, Jorge A.

AU - Grivas, Petros

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Objective: Sarcopenia, or the age-related loss of skeletal muscle mass and function, has been investigated as a potential marker of adverse outcomes among surgical patients. Our aim was to assess for changes in psoas muscle volume (PMV) following administration of neoadjuvant chemotherapy (NAC) in patients with bladder cancer and to examine whether changes in PMV following NAC are predictive of perioperative complications, pathologic response or survival. Methods: During the period of 2009-2013, patients undergoing NAC and radical cystectomy (RC) at our institution with pre and post NAC cross sectional images available were included. Bilateral total psoas muscle volume (PMV) was obtained from pre- and post- NAC images and the proportion of PMV change was calculated by dividing the change PMV by pre-NAC PMV. Analyses for the assessment of factors predicting PMV loss, partial/complete pathologic response (pPR/pCR), complications, readmission, cancer specific (CSS), recurrence-free (RFS) and overall survival (OS) were performed. Results: Total of 60 patients had complete radiological data available. Post-NAC PMV and BMI declines were statistically significant, 4.9% and 0.05%, respectively. NAC dose reduction/delay was a significant predictor of PMV loss (coefficient B 4.6; 95%CI 0.05-9.2; p = 0.047). The proportion ofPMVdecline duringNACwas not a predictor of pPR, pCR, complications, readmission, CSS, RFS, or OS. Conclusions: We observed an interval decline in PMV during the period of NAC administration and this decline was more than it could be appreciated with changes in BMI during the same period. PMV decline was associated with the need for dose reduction/dose delay during NAC. In our series, PMV changes occurring during NAC administration were not predictive of pathologic response to chemotherapy, postoperative complications or survival.

AB - Objective: Sarcopenia, or the age-related loss of skeletal muscle mass and function, has been investigated as a potential marker of adverse outcomes among surgical patients. Our aim was to assess for changes in psoas muscle volume (PMV) following administration of neoadjuvant chemotherapy (NAC) in patients with bladder cancer and to examine whether changes in PMV following NAC are predictive of perioperative complications, pathologic response or survival. Methods: During the period of 2009-2013, patients undergoing NAC and radical cystectomy (RC) at our institution with pre and post NAC cross sectional images available were included. Bilateral total psoas muscle volume (PMV) was obtained from pre- and post- NAC images and the proportion of PMV change was calculated by dividing the change PMV by pre-NAC PMV. Analyses for the assessment of factors predicting PMV loss, partial/complete pathologic response (pPR/pCR), complications, readmission, cancer specific (CSS), recurrence-free (RFS) and overall survival (OS) were performed. Results: Total of 60 patients had complete radiological data available. Post-NAC PMV and BMI declines were statistically significant, 4.9% and 0.05%, respectively. NAC dose reduction/delay was a significant predictor of PMV loss (coefficient B 4.6; 95%CI 0.05-9.2; p = 0.047). The proportion ofPMVdecline duringNACwas not a predictor of pPR, pCR, complications, readmission, CSS, RFS, or OS. Conclusions: We observed an interval decline in PMV during the period of NAC administration and this decline was more than it could be appreciated with changes in BMI during the same period. PMV decline was associated with the need for dose reduction/dose delay during NAC. In our series, PMV changes occurring during NAC administration were not predictive of pathologic response to chemotherapy, postoperative complications or survival.

KW - Bladder cancer

KW - Complications

KW - Cystectomy

KW - Neoadjuvant chemotherapy

KW - Pathologic response

KW - Psoas muscle volume

KW - Sarcopenia

KW - Urothelial cancer

UR - http://www.scopus.com/inward/record.url?scp=85020587558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020587558&partnerID=8YFLogxK

U2 - 10.3233/BLC-160080

DO - 10.3233/BLC-160080

M3 - Article

AN - SCOPUS:85020587558

VL - 3

SP - 57

EP - 63

JO - Bladder Cancer

JF - Bladder Cancer

SN - 2352-3727

IS - 1

ER -